- Health technology company Respiri (RSH) has received its first batch of wheezos, to help with wheeze detection
- Wheezo is a child-friendly, non-invasive device which can detect the presence of wheezing
- Respiri has received its first batch of 500 devices which have now been delivered to the product team
- The company confirmed that 95 per cent of the devices passed the compliance testing
- Respiri is up 7.14 per cent on the market today, selling shares at 7.5¢ apiece
Health technology company Respiri (RSH) has received its first batch of wheezos, to help with wheeze detection.
Wheezing is a high-pitched whistling sound made while you breathe. It’s heard most when you exhale, but in severe cases, it can be heard when you inhale. It is caused by narrowed airways or inflammation.
Asthma and chronic obstructive pulmonary disease (COPD) are the most common causes of wheezing, however, there may be other potential causes, such as heart failure, lung cancer, sleep apnea and more.
Wheezo is a child-friendly, non-invasive device which can detect the presence of wheezing in people diagnosed with asthma before they can. Each wheezo can be used on four people.
The device is also connected to an app which gives an instant reading and tracks symptoms, triggers and the medication plan daily. The app can also share results with a doctor.
Respiri has received its first batch of 500 devices, delivered by SRX to the product team.
The company confirmed that 95 per cent of the devices passed the compliance testing and the team is very pleased with the performance of the wheezo.
The wheezos will be placed in a patient and clinician experiential program.
“This program will provide clinicians & patients full access to the wheezo® eHealth SaaS platform and, in the process, help RSH gain important data and insights that will be key for the full commercial launch scheduled for the fourth quarter of calendar 2020,” the company said.
Respiri is up 7.14 per cent on the market today, selling shares at 7.5¢ apiece at 12:11 pm AEDT.